Pfizer

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Pfizer sits in the top decile of US sponsors by registered trial count (#7 of 15,742 sponsors by registered trial count).

1,845 total trials 106 currently recruiting 1335 completed early-phase tilt top decile by trial count

Pfizer: 1,845 sponsored US clinical trials, 106 recruiting.

Pfizer sponsors 1,845 registered US clinical trials on ClinicalTrials.gov, 106 of them currently recruiting, and 1,335 completed. 504 of these trials are in Phase 3-4 (later-stage) and 1,173 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Healthy, with 44 trials.

Top-decile sponsor footprint

Pfizer ranks in the top decile of sponsors by registered trial count (#7 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

F 39/100

1,335 of 1,673 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (79.8%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

1,845 total, page 3 of 37

RECRUITING Phase 3

A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments

NCT05020236

RECRUITING

Observational Study to Assess Maternal, Fetal and Infant Outcomes Following Exposure to Rimegepant

NCT05046613

RECRUITING Phase 3

Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine

NCT04743141

RECRUITING Phase 3

Randomized Study in Children and Adolescents With Migraine: Acute Treatment

NCT04649242

RECRUITING Phase 1

Study of PF-07248144 in Advanced or Metastatic Solid Tumors

NCT04606446

RECRUITING Phase 1

A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma

NCT03460977

ACTIVE NOT RECRUITING Phase 1

A Study to Learn if a Medicine Called Itraconazole Changes How the Body Processes the Study Medicine PF-08642534 in Healthy Adults.

NCT07575945

ACTIVE NOT RECRUITING

A Study to Learn About Patients With Non-Small Cell Lung Cancer (NSCLC) Who Took Lorlatinib as Their First Treatment

NCT07567352

ACTIVE NOT RECRUITING Phase 1

A Study to Learn About the Effect of Study Medicine Called PF-08653944 on How Quickly the Stomach Empties Its Content in Healthy Adults With Overweight or Obesity

NCT07508241

ACTIVE NOT RECRUITING

A Study to Learn How Effective is PCV20 to Help Stop Adults Who Have a Higher Chance of Getting Pneumonia

NCT07251465

ACTIVE NOT RECRUITING Phase 1

A Study to Learn if Itraconazole Changes How the Body Processes PF-07248144 (Study Medicine)

NCT07335419

ACTIVE NOT RECRUITING

Utilization and Effectiveness of Ritlecitinib in a Real-World Population With Severe AA in the US

NCT07226531

ACTIVE NOT RECRUITING

Evaluating ABRYSVO Maternal Vaccine Effectiveness Among Infants

NCT07249320

ACTIVE NOT RECRUITING Phase 2

A Study to Learn About Study Medicine Called PF-08049820 in People With Eczema

NCT07216027

ACTIVE NOT RECRUITING

A Study to Learn How Paxlovid [Nirmatrelvir-ritonavir/PF-07321332] Works in COVID-19 Patients Who Are Elderly or Have Medical Conditions.

NCT07261085

ACTIVE NOT RECRUITING Phase 1

A Study to Learn If the Study Medicine Called PF-08049820 Changes How the Body Processes the Other Study Medicines Called Oral Contraceptives, Midazolam, and Dabigatran in Healthy Adult Female Participants

NCT07190430

ACTIVE NOT RECRUITING Phase 1

A Study to Learn About the Study Medicine Called PF-08046032 in People With Advanced Cancers

NCT06870487

ACTIVE NOT RECRUITING Phase 1

A Clinical Trial of PF-08046037 Alone or With Sasanlimab in Patients With Advanced or Metastatic Malignancies

NCT06974734

ACTIVE NOT RECRUITING

A Study to Learn About How Well Yearly Updates to the COVID-19 Vaccine Work to Protect People From COVID-19 and How Much Money People Spend on Healthcare for COVID-19

NCT06923137

ACTIVE NOT RECRUITING

Effectiveness of ABRYSVO® Maternal Respiratory Syncytial Virus (RSV) Vaccine Against RSV in Infants in Western Pennsylvania

NCT06813872

ACTIVE NOT RECRUITING

A Study to Learn About the Study Medicine Bosulif in Adult Patients With Chronic Myeloid Leukemia(CML).

NCT06297161

ACTIVE NOT RECRUITING

A Study to Learn About How Well the Prevnar 20 Vaccine Works for Pneumonia in People Who Are 65 Years and Older

NCT06782282

ACTIVE NOT RECRUITING Phase 1

A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene.

NCT06704724

ACTIVE NOT RECRUITING Phase 1

A Study to Learn How Different Amounts of the Study Medicine Called PF-08049820 Are Tolerated and Act in the Body in Healthy Adults

NCT06686797

ACTIVE NOT RECRUITING Phase 2

A Study to Learn About How a New Pneumococcal Vaccine Works in Infants

NCT06524414

ACTIVE NOT RECRUITING

A Real-life Study to Understand the Use and Effects of Palbociclib in US Patients With Breast Cancer

NCT06495164

ACTIVE NOT RECRUITING

Real-World Effectiveness of High-Dose Tafamidis on Neurologic Disease Progression in Mixed-Phenotype Transthyretin Amyloid Cardiomyopathy

NCT06393465

ACTIVE NOT RECRUITING Phase 1

A Study to Learn About Vepdegestrant When Given With PF-07220060 to People With Advanced or Metastatic Breast Cancer.

NCT06206837

ACTIVE NOT RECRUITING Phase 1

TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer. (Sub-Study C)

NCT06125522

ACTIVE NOT RECRUITING Phase 2

A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment

NCT06105632

ACTIVE NOT RECRUITING Phase 1

A Study to Learn About the Safety and Immune Response of a New Pneumococcal Vaccine in Adults

NCT06182124

ACTIVE NOT RECRUITING Phase 1

A Study to Learn About the Study Medicine Called PF-07868489 in Healthy Adult People and in People With Pulmonary Arterial Hypertension

NCT06137742

ACTIVE NOT RECRUITING Phase 3

A 104-Week Study of Ritlecitinib Oral Capsules in Adults With Nonsegmental Vitiligo (Active and Stable) Tranquillo 2

NCT06072183

ACTIVE NOT RECRUITING

A Study to Learn About ABRYSVO Vaccine in Older Adults to Prevent Severe Respiratory Syncytial Virus (RSV) Disease

NCT06077968

ACTIVE NOT RECRUITING

Use and Effectiveness of COVID-19 Vaccines Using State Vaccine Registries and Insurance Claims Data

NCT05876377

ACTIVE NOT RECRUITING Phase 1

A Study to Learn About the Effects of Two Study Medicines (Maplirpacept [PF-07901801] And Glofitamab) When Given Together In People With Relapsed Or Refractory Diffuse Large B Cell Lymphoma.

NCT05896163

ACTIVE NOT RECRUITING Phase 3

Vepdegestrant (ARV-471/PF-07850327) + Palbociclib vs Letrozole + Palbociclib in ER(+)/HER2(-) Advanced Breast Cancer

NCT05909397

ACTIVE NOT RECRUITING Phase 1

To Understand the Safety and Effects of a C. Difficile Vaccine With New Adds-Ons That Will Be Given to Healthy Adults

NCT05805826

ACTIVE NOT RECRUITING Phase 3

A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast Cancer

NCT05654623

ACTIVE NOT RECRUITING Phase 1

TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study B)

NCT05573555

ACTIVE NOT RECRUITING Phase 1

TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study A)

NCT05548127

ACTIVE NOT RECRUITING Phase 3

An Efficacy, Safety, Tolerability, Immunogenicity, and Lot-Consistency Clinical Trial of a 6-Valent OspA-Based Lyme Disease Vaccine (VLA15)

NCT05477524

ACTIVE NOT RECRUITING Phase 2

A Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic Colorectal Cancer

NCT05217446

ACTIVE NOT RECRUITING Phase 2

Study for Participants Continuing From Pfizer-sponsored Palbociclib (a Study Medicine) Studies

NCT05226871

ACTIVE NOT RECRUITING Phase 3

Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant

NCT05317416

ACTIVE NOT RECRUITING Phase 1

A Study to Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid Tumors

NCT05262400

ACTIVE NOT RECRUITING

A Study to Look at the Health Outcomes of Patients With COVID-19 and Influenza

NCT05160636

ACTIVE NOT RECRUITING Phase 4

Lorlatinib Continuation Study

NCT05144997

ACTIVE NOT RECRUITING

Study of Pregnancy Outcomes in Women Exposed to Rimegepant During Pregnancy

NCT05198245

ACTIVE NOT RECRUITING Phase 2

MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma

NCT05090566

← Previous Page 3 of 37 Next →

Phase Distribution

PhaseTrial count
Phase 1 703
Phase 2 470
Phase 3 411
Phase 4 93

What is open in the Pfizer pipeline

106 recruiting of 1,845 indexed (6% open); 1,335 completed (72%).

Phase mix: 504 late (III/IV) vs 1,173 early (I/II) (early-phase heavy).

Top condition: Healthy (44 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Pfizer: open-pipeline peers nationwide

Peers matched on 1,845 registered trials and 6% open enrollment, not the therapeutic-area sidebar.

Pfizer sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 05001,0001,5002,000 5%10%15%20% Total trials Recruiting share PfizerMemorial Sloan Kettering Cancer CenterStanford UniversityDuke UniversityUniversity of California, San FranciscoPacira PharmaceuticalsBioDelivery Sciences InternationalColgate PalmoliveDurham VA Medical Center
Pfizer sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Pfizer sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 1,845 trials (± recruiting share)

Sponsors near 6% open enrollment (± trial volume)

What to do with this Pfizer page

1,845 registered trials is a research-attention snapshot, not an endorsement of Pfizer or any single study.

  • 106 of Pfizer's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Healthy is the condition Pfizer studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Healthy trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Pfizer pipeline card: 1,845 registered trials from official public datasets.Report a data error.